A carregar...
Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry
The authors sought to retrospectively analyze the real‐world evidence on aliskiren in diabetic patients with or without concomitant renin‐angiotensin system (RAS) blocker use based on the Registry for Ambulant Therapy With RAS Inhibitors in Hypertension Patients in Germany (3A). Of 14,986 patients i...
Na minha lista:
| Publicado no: | J Clin Hypertens (Greenwich) |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8031948/ https://ncbi.nlm.nih.gov/pubmed/27094460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12828 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|